Jim Cramer Analyzes Johnson & Johnson After FDA Approval of OTTAVA Robotic System
On July 23, Jim Cramer highlighted a significant shift in investor sentiment toward Johnson & Johnson (JNJ) following the U.S. Food and Drug Administration's approval of its OTTAVA Robotic Surgical System on July 22. The FDA clearance marked J&J’s entry into surgical robotics as the first table-integrated soft-tissue robotic platform, authorized for a range of upper-abdominal procedures such as gastric bypass and gallbladder removal. Cramer had previously advocated buying JNJ after its strong earnings report was initially overlooked by Wall Street. The approval acted as a catalyst that validated his bullish stance on the stock, which surged in response to the news. Cramer emphasized how high-quality defensive stocks like Johnson & Johnson serve as portfolio 'permits' for investors holding aggressive tech positions during market volatility. The company plans a targeted commercial rollout with U.S. hospital partners and is pursuing international approvals while conducting further clinical trials for additional procedures, positioning JNJ to compete in the surgical robotics space against leaders such as Intuitive Surgical (ISRG).
Tickers: $JNJ